Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer |
Jiang, Chang
(State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Liao, Fang-Xin (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Rong, Yu-Ming (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Yang, Qiong (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Yin, Chen-Xi (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) He, Wen-Zhuo (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Cai, Xiu-Yu (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Guo, Gui-Fang (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Qiu, Hui-Juan (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Chen, Xu-Xian (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Zhang, Bei (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) Xia, Liang-Ping (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) |
1 | Roth AD, Fazio N, Stupp R, et al. (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; epirubicin, cisplatin, fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23. DOI ScienceOn |
2 | Shah MA, Jhawer M, Ilson DH, et al. (2011). Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol, 29, 868-74. DOI ScienceOn |
3 | Sparreboom A, Scripture CD, Trieu V, et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res, 11, 4136-43. DOI ScienceOn |
4 | Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. DOI ScienceOn |
5 | Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. DOI ScienceOn |
6 | Lu YF, Liu ZC, Li ZH, et al. (2014). Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. Asian Pac J Cancer Prev, 15, 1419-22. 과학기술학회마을 DOI ScienceOn |
7 | Ji FZ, Zhu WG, Yu CH, et al. (2013). A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma. Chinese J Gastrointestinal Surgery, 16, 842-5. |
8 | Jie. H, Kang. S (2011). The epidemiology, current status of management, challenge and future strategy for esophageal cancer in China. China Oncology, 21, 501-4. |
9 | Jones SE, Erban J, Overmoyer B, et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23, 5542-51. DOI ScienceOn |
10 | Mizota A, Shitara K, Kondo C, et al. (2011). A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology, 81, 237-42. DOI ScienceOn |
11 | Nakajima M, Kato H (2013). Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 14, 1345-54. DOI ScienceOn |
12 | O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J (2013). Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat, 138, 829-37. DOI |
13 | Park SH, Lee WK, Chung M, et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 17, 225-9. DOI ScienceOn |
14 | Gu M, Li SY, Huang XE, et al. (2012). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91. 과학기술학회마을 DOI ScienceOn |
15 | Hsu Y, Sood AK, Sorosky JI (2004). Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol, 27, 14-8. DOI ScienceOn |
16 | Einzig AI, Neuberg D, Remick SC, et al. (1996). Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol, 13, 87-93. DOI ScienceOn |
17 | Esteban E, Gonzalez de Sande L, Fernandez Y, et al. (2003). Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol, 14, 1640-7. DOI ScienceOn |
18 | Fujita Y, Hiramatsu M, Kawai M, et al. (2008). Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus. 21, 496-501. DOI ScienceOn |
19 | Huang J, Cai RG, Meng PJ, et al. (2004). Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus. Chinese J Oncol, 26, 753-5. |
20 | International Agency for Research on Cancer;GLOBOCAN 2012. Available from URL: http://www-dep.iarc.fr/CancerMondial.htm. |
21 | Ilson DH, Ajani J, Bhalla K, et al. (1998). Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol, 16, 1826-34. DOI |
22 | Al-Hajeili M, Azmi AS, Choi M (2014). Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther, 7, 187-92. |
23 | Bang YJ, Van Cutsem E, Feyereislova A, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. DOI ScienceOn |
24 | Ajani JA, Ilson DH, Daugherty K, et al. (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91. DOI ScienceOn |
25 | Ajani JA, Fodor MB, Tjulandin SA, et al. (2005). Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23, 5660-7. DOI ScienceOn |
26 | Burtness B, Gibson M, Egleston B, et al. (2009). Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol, 20, 1242-8. DOI ScienceOn |
27 | Desai N, Trieu V, Yao Z, et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24. DOI ScienceOn |
28 | Desai NP, Trieu V, Hwang LY, et al. (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Grug, 19, 899-909. DOI ScienceOn |
29 | Wu S, Chen MY, Luo JC, Wei L, Chen Z (2012). Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma. Chinese J Oncol, 34, 873-6. |
30 | Dubecz A, Solymosi N, Stadlhuber RJ, et al. (2014). Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century? a SEER Database analysis. J Gastrointest Surg, 18, 124-9. DOI ScienceOn |
31 | Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99, 860-8. DOI ScienceOn |
32 | Zhang P, Xie CY, Wu SX (2007). Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer. Chinese J Oncol, 29, 773-7. |
33 | Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Natl Medical J China, 90, 1986-8. |
34 | Xing PY, Li JL, Wang Y, et al. (2013). Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. Chin J Cancer Res, 25, 200-5. |
35 | Zhang DS, Wang DS, Wang ZQ, et al. (2013). Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol, 71, 1065-72. DOI ScienceOn |
36 | Zhang TR, Zhao T, Xu X, Gu XW, Pan YK (2010). Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy. Chinese J Oncol, 32, 791-4. |
37 | Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ (2012). Analysis of esophageal cancer time trends in China, 1989- 2008. Asian Pac J Cancer Prev, 13, 4613-7. 과학기술학회마을 DOI ScienceOn |
38 | Shi Y, Qin R, Wang ZK, Dai GH (2013). Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther, 6, 585-91. |
39 | Petrasch S, Welt A, Reinacher A, et al. (1998). Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer, 78, 511-4. DOI |
40 | Thallinger CMR, Raderer M, Hejna M (2011). Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy. J Clin Oncol, 29, 4709-14. DOI |
41 | Mirinezhad SK, Jangjoo AG, Seyednejad F, et al. (2014). Impact of tumor length on survival for patients with resected esophageal cancer. Asian Pac J Cancer Prev, 15, 691-4. 과학기술학회마을 DOI ScienceOn |
42 | Von Hoff DD, Ervin T, Arena FP, et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J Med, 369, 1691-703. |